PCD

International Medical Industries, Inc. Announces Partnership with Grifols for Enhanced Medication Safety

Retrieved on: 
Monday, April 8, 2024
Partnership, Safety, Grifols, Patient, PCD, Patient safety, KIRO, IMI, Medical device

POMPANO BEACH, Fla., April 8, 2024 /PRNewswire/ -- International Medical Industries, Inc. (IMI) is thrilled to announce an innovative partnership with Grifols that promises to enhance medication safety through cutting-edge technology.

Key Points: 
  • POMPANO BEACH, Fla., April 8, 2024 /PRNewswire/ -- International Medical Industries, Inc. (IMI) is thrilled to announce an innovative partnership with Grifols that promises to enhance medication safety through cutting-edge technology.
  • IMI, the industry leader in secure drug delivery devices, is joining forces with Kiro Grifols, dedicated to the state-of-the-art automated pharmacy compounding device (PCD), KIRO Fill.
  • Their commitment to quality and patient safety perfectly aligns with Kiro Grifols' mission to deliver innovative solutions that enhance pharmacy automation and accuracy.
  • This strategic partnership aims to reshape the landscape of pharmaceutical compounding, setting a new benchmark for safety, precision, and reliability.

First Bank Announces Fourth Quarter 2023 Net Income of $8.4 Million and Full Year Net Income of $20.9 Million

Retrieved on: 
Wednesday, January 24, 2024
First Bank, Total, KRBA, KBRA, Bank, Interest, Jules Kroll, Environment, Sale, Tax, Investment, Common equity, Federal Home Loan Banks, Acquisition, Information technology, Quarter, PCD, Growth

Net income for the fourth quarter of 2023 was $8.4 million, or $0.33 per diluted share, compared to $9.1 million, or $0.46 per diluted share, for the fourth quarter of 2022.

Key Points: 
  • Net income for the fourth quarter of 2023 was $8.4 million, or $0.33 per diluted share, compared to $9.1 million, or $0.46 per diluted share, for the fourth quarter of 2022.
  • Fourth Quarter and Full Year 2023 Performance Highlights:
    Total net revenue (net interest income plus non-interest income) of $28.0 million for the fourth quarter of 2023 increased $2.8 million, or 11.1%, compared to the prior year quarter, while full year total net revenue was $103.8 million, an increase of $6.3 million, or 6.5%, compared to 2022.
  • Non-interest bearing deposits increased $8.1 million during the fourth quarter of 2023 while interest bearing deposits decreased $7.9 million.
  • The Bank recorded net charge-offs of $209,000 during the fourth quarter of 2023 compared to net charge-offs of $1.1 million in the third quarter of 2023 and net recoveries of $213,000 in the fourth quarter of 2022.

Old National's 4th Quarter and Record Full-Year Results Supported by Strong Deposit Franchise, Stable Credit Quality and Well-Managed Expenses

Retrieved on: 
Tuesday, January 23, 2024
Silicon, FDIC, Central Time, Federal Deposit Insurance Corporation, International, Signature Bank, Sale, Investment, Acquisition, VISA, By-law, Old National Bank, PCD, Silicon Valley Bank, Visa, Bank

A loan to deposit ratio of 89% at December 31, 2023, combined with existing funding sources, provides strong liquidity.

Key Points: 
  • A loan to deposit ratio of 89% at December 31, 2023, combined with existing funding sources, provides strong liquidity.
  • Total commercial loan production in the fourth quarter was $1.3 billion; period-end commercial pipeline totaled $1.7 billion.
  • Average total loans in the fourth quarter were $32.8 billion, an increase of $116.9 million from the third quarter of 2023.
  • Strong credit quality continues to be a hallmark of Old National.

OceanFirst Financial Corp. Announces Quarterly and Annual Earnings and Financial Results

Retrieved on: 
Thursday, January 18, 2024
PTPP, Durbin amendment, FDIC, Credit, Trust, Federal Deposit Insurance Corporation, FHLB, Shareholder, Environment, Sale, Tax, GAAP, Investment, Federal Home Loan Banks, Annual general meeting, PCD, OceanFirst Bank, Growth, Bank

1 Core earnings and core earnings before income taxes and provision for credit losses (“PTPP or Pre-Tax-Pre-Provision”), and ratios derived therefrom, are non-GAAP financial measures.

Key Points: 
  • 1 Core earnings and core earnings before income taxes and provision for credit losses (“PTPP or Pre-Tax-Pre-Provision”), and ratios derived therefrom, are non-GAAP financial measures.
  • Refer to “Explanation of Non-GAAP Financial Measures” and the “Non-GAAP Reconciliation” tables for additional information regarding non-GAAP financial measures.
  • Refer to “Explanation of Non-GAAP Financial Measures” and the “Non-GAAP Reconciliation” tables for additional information regarding non-GAAP financial measures.
  • OceanFirst Financial Corp.’s subsidiary, OceanFirst Bank N.A., founded in 1902, is a $13.5 billion regional bank providing financial services throughout New Jersey and in the major metropolitan markets of Philadelphia, New York, Baltimore, and Boston.

ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia

Retrieved on: 
Wednesday, January 3, 2024
Science, Other Science, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, LNP, Quality of life, DNAI1, Virus, Messenger, FDA, PCD, Cilium, Disease, MBA, Bacteria, Recode, Therapy, Mucus, Volunteering, Patient, Diagnosis, Safety, Primary ciliary dyskinesia, DSM-IV codes, Disorder, Vaccine

“This is the first time a patient with PCD has received a targeted mRNA-based therapeutic,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of ReCode Therapeutics.

Key Points: 
  • “This is the first time a patient with PCD has received a targeted mRNA-based therapeutic,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of ReCode Therapeutics.
  • “This study will evaluate RCT1100 as a potential novel treatment option for patients who do not have any approved therapies.
  • The DNAI1 mRNA is intended to establish or restore proper ciliary function by addressing the underlying cause of the disease.
  • This study brings us one step closer to improving the respiratory health and quality of life of people living with this disease.”

TriMas Packaging Group to Exhibit at Paris Packaging Week 2024

Retrieved on: 
Thursday, December 28, 2023
Manufacturing, Cosmetics, Retail, Packaging, Chemicals, Plastics, PCD, Beauty, Masco, Booth

TriMas Packaging, the largest division of TriMas (NASDAQ: TRS), will exhibit at Paris Packaging Week 2024 at the Paris Expo Porte de Versailles on January 17-18th.

Key Points: 
  • TriMas Packaging, the largest division of TriMas (NASDAQ: TRS), will exhibit at Paris Packaging Week 2024 at the Paris Expo Porte de Versailles on January 17-18th.
  • TriMas Packaging, and its market-leading brands, consisting of Rieke®, Aarts Packaging, Affaba & Ferrari™, Taplast™ and Rapak®, will be showcasing its most innovative and sustainable product solutions for the beauty and personal care markets.
  • “As the beauty packaging industry continues to evolve, consumers are seeking a more personalized and premium experience,” said Fabio Salik, TriMas Packaging Group President.
  • “The Paris Packaging Week show is the ideal forum for us to present our most innovative and highly customizable offerings in the growing beauty and cosmetic sector.

TriMas Packaging Group to Exhibit at Paris Packaging Week 2024

Retrieved on: 
Thursday, December 28, 2023
Packaging, Other Manufacturing, Manufacturing, PCD, Beauty, Masco, Booth

TriMas Packaging, the largest division of TriMas (NASDAQ: TRS), will exhibit at Paris Packaging Week 2024 at the Paris Expo Porte de Versailles on January 17-18th.

Key Points: 
  • TriMas Packaging, the largest division of TriMas (NASDAQ: TRS), will exhibit at Paris Packaging Week 2024 at the Paris Expo Porte de Versailles on January 17-18th.
  • TriMas Packaging, and its market-leading brands, consisting of Rieke®, Aarts Packaging, Affaba & Ferrari™, Taplast™ and Rapak®, will be showcasing its most innovative and sustainable product solutions for the beauty and personal care markets.
  • “As the beauty packaging industry continues to evolve, consumers are seeking a more personalized and premium experience,” said Fabio Salik, TriMas Packaging Group President.
  • “The Paris Packaging Week show is the ideal forum for us to present our most innovative and highly customizable offerings in the growing beauty and cosmetic sector.

Samsung Ushers in a New Era of Diagnostic Solutions at RSNA 2023

Retrieved on: 
Tuesday, November 21, 2023
Biotechnology, Technology, Other Health, Health, General Health, Radiology, Health Technology, Other Technology, Medical Devices, Mobile, Wireless, Hardware, Photon, X-ray, RSNA, Neck, Associate, Next Generation, Research, Annual general meeting, Steven Novella, Head, University, ICU, Level 4, PCD, Patient, Multimedia, Samsung Electronics, McCormick Place, Neuroradiology, FDA, Stroke, Booth, US FDA, MD, Harvard Medical School, Trauma, VMI, Massachusetts General Hospital, Doctor of Philosophy, CST, Samsung, Hospital, MCT, Medical imaging, Medical device

View the full release here: https://www.businesswire.com/news/home/20231121501923/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231121501923/en/
    The high-tech, yet highly mobile OmniTom Elite with Photon Counting Detector (PCD) CT scanner is designed to offer advanced imaging at the point-of-care.
  • In the near term, all current OmniTom users will have the opportunity to upgrade their scanners with the PCD technology.
  • Meanwhile, a limited number of premier research partners will aid in developing the full potential of OmniTom Elite with PCD.
  • OmniTom Elite with PCD is only supported for adult axial imaging for head and neck.

Hyperion expands PCD offering with addition of 2 new product lines

Retrieved on: 
Thursday, November 9, 2023
Diamond, Electronics, PCD, Copper, Wood, CFRP, MDF, Aluminium, U series, Industrial design, Forging, Hyperion

WORTHINGTON, Ohio, Nov. 9, 2023 /PRNewswire/ -- Hyperion Materials & Technologies, a leading manufacturer of hard and super-hard materials for a variety of demanding industrial applications, is excited to announce the launch of two new polycrystalline diamond (PCD) lines, the P-Series and U-Series, that expand the company's offering to the toolmaking industry.

Key Points: 
  • "Hyperion is excited to offer these new product lines alongside its industry-leading premium COMPAX® PCD line."
  • U-Series PCD is explicitly designed for tools used in machining nonferrous and nonmetallic workpieces in woodworking, heavy machinery, and other utility applications.
  • This product line enables toolmakers to optimize costs without sacrificing reliability in machining applications where competitiveness and consistency are critical.
  • Learn more about P-Series and U-Series PCD by visiting Hyperion's PCD product pages .

Byline Bancorp, Inc. Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, October 26, 2023
Banking, Professional Services, Finance, PCD, Sale, Federal Home Loan Banks, Government, ACL, Telephone, GAAP, Acquisition, ASU, Webcast, Central Time, Current Expected Credit Losses, Annual report, Bank, Cryptocurrency, Rare-earth element, Real estate

Net interest income for the third quarter of 2023 was $92.5 million, an increase of $16.3 million, or 21.4%, from the second quarter of 2023.

Key Points: 
  • Net interest income for the third quarter of 2023 was $92.5 million, an increase of $16.3 million, or 21.4%, from the second quarter of 2023.
  • Tax-equivalent net interest margin1 for the third quarter of 2023 was 4.47%, an increase of 14 basis points compared to the second quarter of 2023.
  • Our efficiency ratio was 53.75% for the third quarter of 2023 compared to 52.92% for the second quarter of 2023.
  • Excluding significant items, our adjusted efficiency ratio1 for the third quarter 2023 was 47.35%, compared to 51.39% for the second quarter of 2023.